Your browser doesn't support javascript.
loading
Do myeloproliferative neoplasms and multiple myeloma share the same genetic susceptibility loci?
Macauda, Angelica; Giaccherini, Matteo; Sainz, Juan; Gemignani, Federica; Sgherza, Nicola; Sánchez-Maldonado, José Manuel; Gora-Tybor, Joanna; Martinez-Lopez, Joaquin; Carreño-Tarragona, Gonzalo; Jerez, Andrés; Spadano, Raffaele; Golos, Aleksandra; Jurado, Manuel; Hernández-Mohedo, Francisca; Mazur, Grzegorz; Tavano, Francesca; Butrym, Aleksandra; Várkonyi, Judit; Canzian, Federico; Campa, Daniele.
Afiliación
  • Macauda A; Department of Biology, University of Pisa, Pisa, Italy.
  • Giaccherini M; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Sainz J; Department of Biology, University of Pisa, Pisa, Italy.
  • Gemignani F; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Sgherza N; Genomic Oncology Area, GENYO. Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.
  • Sánchez-Maldonado JM; Monoclonal Gammopathies Unit, University Hospital Virgen de las Nieves, Granada, Spain.
  • Gora-Tybor J; Pharmacogenetics Unit, Instituto de Investigación Biosanitaria de Granada (Ibs. Granada), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.
  • Martinez-Lopez J; Department of Medicine, University of Granada, Granada, Spain.
  • Carreño-Tarragona G; Department of Biology, University of Pisa, Pisa, Italy.
  • Jerez A; Division of Hematology, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
  • Spadano R; Pharmacogenetics Unit, Instituto de Investigación Biosanitaria de Granada (Ibs. Granada), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.
  • Golos A; Department of Medicine, University of Granada, Granada, Spain.
  • Jurado M; Department of Hematology, Medical University of Lódz, Lódz, Poland.
  • Hernández-Mohedo F; CNIO, CIBERONC, Complutense University, Hospital 12 de Octubre, Madrid, Spain.
  • Mazur G; CNIO, CIBERONC, Complutense University, Hospital 12 de Octubre, Madrid, Spain.
  • Tavano F; Hematology and Medical Oncology Department, Hospital Morales Meseguer, IMIB, Murcia, Spain.
  • Butrym A; Division of Hematology, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
  • Várkonyi J; Department of Clinical Oncology and Chemotherapy, Magodent Hospital, Warsaw, Poland.
  • Canzian F; Genomic Oncology Area, GENYO. Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, Spain.
  • Campa D; Pharmacogenetics Unit, Instituto de Investigación Biosanitaria de Granada (Ibs. Granada), Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.
Int J Cancer ; 148(7): 1616-1624, 2021 04 01.
Article en En | MEDLINE | ID: mdl-33038278
ABSTRACT
Myeloproliferative neoplasms (MPNs) are a group of diseases that cause myeloid hematopoietic cells to overproliferate. Epidemiological and familial studies suggest that genetic factors contribute to the risk of developing MPN, but the genetic susceptibility of MPN is still not well known. Indeed, only few loci are known to have a clear role in the predisposition to this disease. Some studies reported a diagnosis of MPNs and multiple myeloma (MM) in the same patients, but the biological causes are still unclear. We tested the hypothesis that the two diseases share at least partly the same genetic risk loci. In the context of a European multicenter study with 460 cases and 880 controls, we analyzed the effect of the known MM risk loci, individually and in a polygenic risk score (PRS). The most significant result was obtained among patients with chronic myeloid leukemia (CML) for PS0RS1C1-rs2285803, which showed to be associated with an increased risk (OR = 3.28, 95% CI 1.79-6.02, P = .00012, P = .00276 when taking into account multiple testing). Additionally, the PRS showed an association with MPN risk when comparing the last with the first quartile of the PRS (OR = 2.39, 95% CI 1.64-3.48, P = 5.98 × 10-6 ). In conclusion, our results suggest a potential common genetic background between MPN and MM, which needs to be further investigated.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Predisposición Genética a la Enfermedad / Mieloma Múltiple / Trastornos Mieloproliferativos Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Cancer Año: 2021 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Predisposición Genética a la Enfermedad / Mieloma Múltiple / Trastornos Mieloproliferativos Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Int J Cancer Año: 2021 Tipo del documento: Article País de afiliación: Italia